Sentrx, a New Jersey drug safety specialty firm, announced today that the company grew the number of pharmacovigilance outsourcing contracts by more than 50% in 2008. Revenues for the year increased 25% over 2007. The domestic service provider added long-term contracts in clinical trial and post-marketing safety, managed safety system hosting, and risk evaluation and mitigation strategies. The company maintained its strong record of regulatory compliance during this period of growth.
Little Falls, NJ (PRWEB) January 20, 2009 - Sentrx, the leading provider of drug safety services, announced today that the company grew the number of pharmacovigilance outsourcing contracts by more than 50% in 2008. Revenues for the year increased 25% over 2007.
Sentrx pioneered the concept of drug safety outsourcing and safety system hosting for clinical trials and post-marketed products in 1999. Since that time, Sentrx has provided operational and consulting services to nearly eighty unique clients. More than fifty of those companies have outsourced adverse event processing, safety system management, or risk evaluation and mitigation strategies (REMS) to Sentrx.
Sentrx provides services from its headquarters in Little Falls, NJ. In addition to a staff of office-based health care professionals, the company utilizes its network of highly experienced drug safety investigators across the United States. This flexible workforce allows Sentrx to handle volume fluctuations and extended coverage hours for its clients, which benefit from the quality, reliability and convenience of a domestic service provider.
Highlights of new business in 2008 include:
Copyright©2009 Vocus, Inc.
All rights reserved